Document:

Letter Agreement

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  
 Exhibit 10.42 
  
 Robert J. Beall, Ph.D. 
 Cystic Fibrosis Foundation Therapeutics, Inc.

 6931 Arlington Road 
 Bethesda, MD 20814 
  
 Dear Dr.Beall: 
  
 The purpose of this letter agreement is to amend the Study Funding Agreement, dated June 17, 2003, between the undersigned parties (the
“Agreement”). By signing below, the undersigned parties agree to hereby amend the Agreement as follows: 
  

	 	1.	In Section 8.1(c) of the Agreement, [ * ] shall be replaced with [ * ]. 

  
 All other terms and provisions of the Agreement shall remain unchanged and are in full force and effect. 
  

			
	 HOLLIS-EDEN PHARMACEUTICALS, INC.

		
	 By:
	 	 /s/ E. Loumeau

	 	 	 Eric J. Loumeau
 Vice President, General Counsel

	
	Agreed to and Acknowledged by:
	
	CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC.
		
	By:	 	/s/ R. Beall
	 	 	 Robert J. Beall, Ph.D.
 President and
CEOLetter Agreement

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  
 Exhibit 10.43 
  
 Chris Penland, Ph.D. 
 Cystic Fibrosis Foundation Therapeutics, Inc.

 6931 Arlington Road 
 Bethesda, MD 20814 
  
 Dear Dr. Penland: 
  
 The purpose of this letter agreement is to amend the Study Funding Agreement, dated June 17, 2003, as amended, between the undersigned
parties (the “Agreement”). By signing below, the undersigned parties agree to hereby amend the Agreement as follows: 
  

	 	1.	In Section 2.2 of the Agreement, the Work Plan shall be amended to include the following: 

  

	 	a.	“Performing pre-clinical animal experiments in a mouse model of cystic fibrosis, and 

  

	 	b.	Performing a phase I safety study in cystic fibrosis patients.” 

  

	 	2.	In Section 8.1(c) of the Agreement, [ * ] shall be replaced with [ * ]. 

  

	 	3.	Exhibit B of the Agreement shall be replaced in its entirety with the attached Exhibit B. 

  
 All other terms and provisions of the Agreement shall remain unchanged and are in full force and effect.

  

			
	 HOLLIS-EDEN PHARMACEUTICALS, INC.

		
	 By:
	 	 /s/ E. Loumeau

	 	 	 Eric J. Loumeau
 Vice President, General Counsel

	
	Agreed to and Acknowledged by:
	
	CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC.
		
	By:	 	/s/ R. Beall
	 	 	 Robert J. Beall, Ph.D.
 President and
CEO

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  
 EXHIBIT B 
  
 BUDGET 
  
 Total Budget: $1,700,000.00 
  
 To be paid as follows: 
  
 [ * ] 
  
 Payments will be made via express mail by check payable to:

  
 Hollis Eden Pharmaceuticals, Inc. 
 4435 Eastgate Mall, Suite 400 
 San Diego, CA 92121 

	Attn:	Robert Weber 

 Phone: 858-587-9333 
  
 Tax ID all other:Letter Agreement

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  
 Exhibit 10.44 
  
 July 12, 2004 
  
 Chris Penland, Ph.D. 
 Cystic Fibrosis Foundation Therapeutics, Inc. 
 6931 Arlington Road 
 Bethesda, MD 20814 
  
 Dear Dr. Penland: 
  
 The purpose of this letter agreement is to amend the Study Funding Agreement, dated June 17, 2003, as amended, between the undersigned
parties (the “Agreement”). By signing below, the undersigned parties agree to hereby amend the Agreement as follows: 
  

	 	1.	Section 8.4(a) shall be restated in its entirety as follows: 

  
 “(a) Termination, relinquishment or expiration of this Agreement for any reason shall be without prejudice to any rights that shall
have accrued to the benefit of any Party prior to such termination, relinquishment or expiration. Such termination, relinquishment or expiration shall not relieve any Party from obligations which are expressly indicated to survive termination of
this Agreement. At the time of termination of this Agreement, CFFT shall pay H-E for (i) all payments due pursuant to Exhibit B as of the effective date of termination, (ii) all costs incurred and all non-cancelable commitments, as of the
effective date of termination, in excess of any milestone payments previously paid and (iii) any reasonable costs of bringing the Study to an orderly and prompt termination.” 
  

	 	2.	Exhibit B of the Agreement shall be replaced in its entirety with the attached Exhibit B. 

  
 All other terms and provisions of the Agreement shall remain unchanged and are in full force and effect. 
  

			
	 HOLLIS-EDEN PHARMACEUTICALS, INC.

		
	 By:
	 	 /s/ E. Loumeau

	 	 	 Eric J. Loumeau
 Vice President, General Counsel

	
	Agreed to and Acknowledged by:
	
	CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC.
		
	By:	 	/s/ R. Beall
	 	 	 Robert J. Beall, Ph.D.
 President and
CEO

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  
 EXHIBIT B 
  
 BUDGET 
  
 Total Budget: $1,700,000.00 
  
 To be paid as follows: 
  
 [ * ] 
  
 Payments will be made via express mail by check payable to:

  
 Hollis Eden Pharmaceuticals, Inc. 
 4435 Eastgate Mall, Suite 400 
 San Diego, CA 92121 

	Attn:	Robert Weber 

 Phone: 858-587-9333 
  
 Tax ID all other:Letter Agreement

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  
 Exhibit 10.45 
  
 October 19, 2004 
  
 Chris Penland, Ph.D. 
 Cystic Fibrosis Foundation Therapeutics, Inc. 
 6931 Arlington Road 
 Bethesda, MD 20814 
  
 Dear Dr. Penland: 
  
 The purpose of this Letter Agreement is to amend the Study Funding Agreement, dated June 17, 2003, as amended, between the undersigned
parties (the “Agreement”). By signing below, the undersigned parties agree as follows: 
  

	 	1.	In Section 8.1(c) of the Agreement, [ * ] shall be replaced with [ * ]. 

  

	 	2.	CFFT’s obligation to make the [ * ] under Exhibit B of the Agreement for [ * ] is hereby waived. 

  

	 	3.	CFFT shall pay Hollis-Eden [ * ], which payment shall be made within thirty (30) days. 

  

	 	4.	Within [ * ], the parties shall mutually agree in writing to: 

  

	 	a.	a revised Work Plan under Section 2.2 of the Agreement, and 

  

	 	b.	a revised Exhibit B which shall reflect the revised Work Plan. 

  

	 	5.	The revised Exhibit B shall become part of this Agreement. 

  
 All other terms and provisions of the Agreement shall remain unchanged and are in full force and effect. 
  

			
	 HOLLIS-EDEN PHARMACEUTICALS, INC.

		
	 By:
	 	 /s/ E. Loumeau

	 	 	 Eric J. Loumeau
 Vice President, General Counsel

	
	Agreed to and Acknowledged by:
	
	CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC.
		
	By:	 	/s/ R. Beall
	 	 	 Robert J. Beall, Ph.D.
 President and
CEOLetter Agreement

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  
 Exhibit 10.46 
  
 January 6, 2005 
  
 Chris Penland, Ph.D. 
 Cystic Fibrosis Foundation Therapeutics, Inc. 
 6931 Arlington Road 
 Bethesda, MD 20814 
  
 Dear Dr. Penland: 
  
 The purpose of this Letter Agreement is to amend the Study Funding Agreement, dated June 17, 2003, as amended, between the undersigned
parties (the “Agreement”). 
  
 By signing below, the undersigned parties
agree to extend, for an additional [ * ], the time to agree upon (i) a revised Work Plan under Section 2.2 of the Agreement and (ii) a revised Exhibit B which shall reflect the revised Work Plan. 
  
 All other terms and provisions of the Agreement shall remain unchanged and are in full force
and effect. 
  

			
	 HOLLIS-EDEN PHARMACEUTICALS, INC.

		
	 By:
	 	 /s/ E. Loumeau

	 	 	 Eric J. Loumeau
 Vice President, General Counsel

	
	Agreed to and Acknowledged by:
	
	CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC.
		
	By:	 	/s/ R. Beall
	 	 	 Robert J. Beall, Ph.D.
 President and
CEOLetter Agreement

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  
 Exhibit 10.47 
  
 

 
  
 May 16, 2005 
  
 Richard B. Hollis 
 Hollis-Eden Pharmaceuticals, Inc. 
 4345 Eastgate Mall, Suite 400 
 San Diego, CA 92121 
  
 Dear Mr. Hollis: 
  
 The purpose of this
letter agreement (Amendment 6) is to amend further the contract dated June 18, 2003. By signing below, the undersigned parties hereby agree to amend [ * ] of Exhibit B and replace them with [ * ] as reflected below: 
  
 [ * ] 
  

						
	 	 	      Total	  	$	1,700,000
	 	 	 	  	
	

  
 [ * ] 
  

 Page 1 

 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  

									
	 CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC.

					
	 By:
	 	 /s/ R. Beall
	 	 	 	 	 	 /s/ P. Campbell

	 	 	 Robert J. Beall, Ph.D.
 President and CEO
	 	 	 	 	 	 Preston W. Campbell, III, M.D.
 Executive Vice President of Medical Affairs

  

									
	 	 	HOLLIS-EDEN PHARMACEUTICALS, INC.	 	 	 	 	 	 
					
	 By:
	 	 /s/ Richard B. Hollis
	 	 	 	 	 	 
	 	 	 Richard B. Hollis
 President
	 	 	 	 	 	 

  

 Page 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00090-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00090-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00090-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00090-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00090-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00090-of-00352.parquet"}]]